Oncotelic Therapeutics (OTCQB: OTLC) announced that its subsidiary Sapu Nano will present new data on everolimus toxicology at the Society of Toxicology 2026 Annual Meeting and ToxExpo in San Diego. The presentation, scheduled for 2026, will highlight findings on tissue concentration–driven effects and organ-specific outcomes beyond traditional plasma pharmacokinetics. This research underscores the importance of tissue-level drug distribution in determining toxicity profiles and supports the development of improved delivery strategies, including intravenous and nanoparticle-based formulations.
Everolimus is a widely used mTOR inhibitor for various cancers, but its clinical utility is limited by systemic toxicity. The Sapu Nano study reveals that drug concentration in tissues, rather than in plasma, is a more accurate predictor of adverse effects. By analyzing everolimus distribution in organs such as the liver, kidneys, and lungs, the researchers identified tissue-specific toxicity thresholds that could guide safer dosing regimens. These insights are critical for designing nanoparticle formulations that target drug delivery to tumors while sparing healthy tissues, potentially enhancing the therapeutic index of everolimus.
Oncotelic Therapeutics, through its wholly owned subsidiary Sapu Nano, is focused on developing next-generation nanomedicine platforms to improve drug delivery and unlock new clinical potential for established therapeutics. The company’s pipeline includes treatments for rare pediatric cancers such as Diffuse Intrinsic Pontine Glioma (DIPG) and acute myeloid leukemia. Oncotelic also leverages artificial intelligence through its acquisition of PointR Data Inc. to accelerate drug development.
The presentation at SOT 2026 is expected to attract attention from researchers and clinicians interested in nanomedicine and toxicology. By demonstrating the value of tissue-level pharmacokinetics, Sapu Nano aims to advance the field of targeted drug delivery, potentially leading to safer and more effective cancer therapies. The full press release is available at https://ibn.fm/kZzE3.
Oncotelic continues to build on its expertise in oncology drug development, with a special emphasis on rare pediatric cancers. The company holds rare pediatric disease designations for DIPG, melanoma, and acute myeloid leukemia. Its acquisition of AL-101 for intranasal delivery of apomorphine expands its pipeline into neurological disorders such as Parkinson's disease. For more information on Oncotelic, refer to its 2024 Annual Report on Form 10-K filed with the SEC on April 15, 2025.
The Society of Toxicology meeting is a premier event for toxicology research, and Sapu Nano’s participation highlights the growing importance of nanomedicine in addressing drug toxicity. The data presented could pave the way for clinical trials of nanoparticle-based everolimus formulations, offering new hope for patients who currently face dose-limiting side effects. Oncotelic’s commitment to innovation in drug delivery is evident in its continued investment in Sapu Nano’s platform, which aims to enhance the therapeutic index of both established and novel therapeutics.
